Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioAlliance Pharma will present promising in vivo results for a New Entityat 15th congress of f European Society of Gene and Cell Therapy

Abstract:
BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, said today it will present the first promising in vivo results for its New Entity AMEP, invasive melanoma drug candidate (BA 015 program), at the 15th congress of the European Society of Gene and Cell Therapy, Rotterdam, October 27-30.

BioAlliance Pharma will present promising in vivo results for a New Entityat 15th congress of f European Society of Gene and Cell Therapy

Paris, France | Posted on October 22nd, 2007

These research results complement BioAlliance Pharma's activities in innovative drug delivery methods, which have enabled it to bring a product to market, and carry out clinical programs including three ongoing Phase III trials, while pursuing basic research into new therapeutic targets in HIV and cancer.

The latest results are in the field of oncology where the company has focused on new targets, particularly those implicated in resistance and tumoral invasion (cytoskeleton). The development of AMEP is part of this strategy. AMEP is an anti-angiogenic and anti-proliferative peptide, which binds to the integrins of activated endothelial and cancerous cells.

The Company has developed a plasmid that allows the expression of AMEP in vivo. It will give data on its properties and its anti-tumoral efficacy at the ESGCT congress. AMEP or plasmid AMEP (BA 015 program) is a BioAlliance Pharma drug candidate with potential use against invasive melanoma.

BioAlliance Pharma is collaborating closely with international experts in angiogenesis and oncology at Inserm (Saint Louis Hospital) and the Institut Gustave Roussy. "BioAlliance's work with Inserm and the IGR is an excellent example of the company's academic alliances' with the major French research laboratories focusing on human health," said Professor Christian Auclair, CSO at BioAlliance Pharma. "These alliances give the company continued access to cutting edge science."

Two patent families protect this program internationally as part of BioAlliance Pharma's vigorous intellectual property policy.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance. The Company is currently conducting 3 phase III clinical trials on innovative products. Two products are based on the Lauriad® mucoadhesive technology, which allows an early and prolonged release of therapeutic agents at the site of the disease: one authorized product in France and two clinical international phase III trials ongoing (Loramyc® and acyclovir Lauriad®). One product is based on the Transdrug® nanoparticle technology designed specifically for intracellular targeting: one international phase III trial ongoing on primary liver cancer (doxorubicin Transdrug®). The company develops also a New Entities program focused on new targets in oncology and HIV. The company concluded two strategic partnerships in 2007 to sell its Loramyc® product in Europe and in the US. BioAlliance Pharma has just announced the launch of Loramyc® on the French market.

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website www.amf-france.org or BioAlliance Pharma S.A.’s website http://www.bioalliancepharma.com .

For press release and other company information, visit http://www.bioalliancepharma.com. BioAlliance Pharma SA

For more information, please click here

Contacts:
Dominique COSTANTINI Nicolas FELLMANN
President and CEO
Tel : +33 1 45 58 76 01


Nicolas FELLMANN
CFO
Tel: + 33 1 45 58 76 00


ACTUS Agnès GILBERT
Tel : +33 1 53 67 36 33


Andrew Lloyd & Associates
Andrew Lloyd Juliette
DOS SANTOS
Tel : +33 1 56 54 07 07
Tel : +33 1 56 54 07 04

Copyright © BioAlliance Pharma SA

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Taking the guesswork out of cancer therapy: New molecular test kit predicts patient’s survival and drug response August 1st, 2014

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Announcements

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE